by Pete Celano | Feb 6, 2026 | Blog
A common question is what is HCC, and how prevalent is it in US adults? Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, originating in the main liver cells (hepatocytes). Often linked to chronic liver disease, cirrhosis, or infections...
by Taylor White | Feb 5, 2026 | Blog
At LiverRight, we’ve built our clinic around one core idea: early detection changes outcomes. Whether it’s diagnosing MASLD/NASH in its earliest, reversible stages or accelerating access to specialist care across all 50 states, our goal has always been to make...
by Brandon Tudor | Feb 3, 2026 | Blog
The HEP Mag article “Closing equity gaps in cirrhosis & liver cancer care” is eye-opening. Summary: Closing Equity Gaps in Cirrhosis and Liver Cancer Care Two new studies from UT Southwestern highlight how trust, communication, health literacy, and access to...
by Pete Celano | Jan 29, 2026 | Blog
The Major Reasons (Ranked by Impact) 1️⃣ Hepatology Isn’t a Formal Board Specialty Hepatology is a sub-subspecialty of GI, not a standalone board-certified specialty. You have to: Complete Internal Medicine Complete GI fellowship Then do additional...
by Brandon Tudor | Jan 27, 2026 | Blog
Here’s a summary of the Diabetes In Control article about GLP-1 drugs and liver disease titled “GLP‑1s and Liver Disease: Rethinking MASLD Care Beyond Obesity and A1C.” 📌 The Core Message GLP-1 receptor agonists — originally developed for type 2 diabetes...
by Pete Celano | Jan 25, 2026 | Blog
Yes, liver disease at F1–F2 fibrosis is often reversible, especially if you remove the underlying cause and intervene early. Key word: EARLY. Let’s dig into the details below. 🔬 What F1–F2 actually means Fibrosis stages reflect scar tissue, not permanent loss of...
